Mark Goldsmith is President and Chief Executive Officer of Revolution Medicines, Inc. (RVMD). The company reported total compensation of $14,672,390 for fiscal year 2025.
| Salary | $812,500 |
|---|---|
| Bonus | $0 |
| Stock awards | $3,968,076 |
| Option awards | $8,995,114 |
| Non-equity incentive plan | $889,700 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $7,000 |
| Total | $14,672,390 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Revolution Medicines, Inc. filed April 27, 2026, accession 0001193125-26-182453.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Mark Goldsmith this page | President and Chief Executive Officer | $14,672,390 |
| Stephen Kelsey | President, Research and Development | $5,963,229 |
| Margaret Horn | Chief Operating Officer | $4,821,057 |
| Jeffrey Cislini | General Counsel and Secretary | $3,718,589 |
| Jack Anders | Chief Financial Officer | $3,588,111 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Revolution Medicines, Inc. compensation brief.
Mark Goldsmith's compensation sits inside Revolution Medicines, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.